AAA
PTGX icon

Affinity Asset Advisors’s Protagonist Therapeutics PTGX Stock Holding History

Affinity Asset Advisors’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.1M Hold
172,125
– – 0.94% 33
2025
Q4 		$15M Sell
172,125
-48,475
-22% -$3.97M 0.86% 35
2025
Q3 		$14.7M Sell
220,600
-219,400
-50% -$12.5M 1.28% 24
2025
Q2 		$24.3M Buy
440,000
+40,000
+10% +$1.92M 3.32% 9
2025
Q1 		$19.3M Buy
400,000
+270,000
+208% +$11.3M 1.85% 14
2024
Q4 		$5.02M Buy
+130,000
New +$5.67M 0.67% 38
2024
Q2 		– Sell
-100,000
Closed -$2.89M – 117
2024
Q1 		$2.89M Buy
+100,000
New +$2.72M 0.36% 67
2022
Q2 		– Sell
-300,000
Closed -$7.1M – 63
2022
Q1 		$7.1M Buy
300,000
+58,881
+24% +$1.66M 1.14% 15
2021
Q4 		$8.25M Buy
+241,119
New +$7.62M 2.99% 9
2021
Q3 		– Sell
-140,100
Closed -$6.29M – 88
2021
Q2 		$6.29M Buy
140,100
+90,100
+180% +$2.97M 2.25% 13
2021
Q1 		$1.29M Buy
+50,000
New +$1.27M 0.44% 44

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Affinity Asset Advisors's PTGX Position: Q1 2026 in Review

Affinity Asset Advisors held its Protagonist Therapeutics (PTGX) position steady in Q1 2026 at 172,125 shares worth $18.1M. The position accounts for 0.94% of the portfolio, ranked #33.

Affinity Asset Advisors first reported a position in PTGX in Q1 2021 and has held it in 11 quarters since. The position peaked at $24.3M in Q2 2025. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Affinity Asset Advisors held 172,125 shares of Protagonist Therapeutics worth $18.1M as of Q1 2026.
  • Affinity Asset Advisors left its Protagonist Therapeutics share count unchanged in Q1 2026.
  • Protagonist Therapeutics made up 0.94% of Affinity Asset Advisors's portfolio in Q1 2026, its #33 holding.
  • Affinity Asset Advisors first reported a position in Protagonist Therapeutics in Q1 2021 and has held it in 11 quarters since.
  • Affinity Asset Advisors's Protagonist Therapeutics position peaked at $24.3M in Q2 2025.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.